Article

Journal of Autism and Developmental Disorders

, Volume 35, Issue 3, pp 387-391

First online:

Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders

  • Antonio Y. HardanAffiliated withWestern Psychiatric Institute and Clinic, University of Pittsburgh School of MedicineWestern Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine Email author 
  • , Roger J. JouAffiliated withDepartment of Psychiatry, Yale University School of Medicine
  • , Benjamin L. HandenAffiliated withWestern Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

A retrospective study was conducted in a clinic specialized in treating individuals with developmental disabilities to examine the effectiveness and tolerability of quetiapine in children and adolescents with pervasive developmental disorders. Ten consecutive outpatients (age = 12.0 ± 5.1 years) treated with quetiapine (dose = 477 ± 212 mg, duration = 22.0 ± 10.1 weeks) were identified and six were judged to be responders based on impressions from chart review and Conners Parent Scale (CPS). Improvements were observed in the conduct, inattention, and hyperactivity subscales of the CPS. Adverse events were mild with sedation being the most common, and no patient required treatment termination. Quetiapine may be beneficial in children and adolescents with pervasive developmental disorders, however open-label and double-blind, placebo-controlled studies are warranted.

Keywords

Quetiapine antipsychotic agents autism pervasive developmental disorder children adolescents